Skip to content
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
Qvanteq

Qvanteq AG is a Top 100 Swiss Startup

By qvanteq17. September 20147. February 20182014, News

Qvanteq was amongst the “Top 100 Swiss Startups”  for the 4th time in a row.

Post navigation

CTI Swiss medtech best poster award 2014
First patient enrolled in the QUEST I clinical study

Recent News

  • Reduced thrombogenicity of surface-treated Nitinol implants steered by altered protein adsorption
  • Stop the activation of the blood coagulation cascade by your medical device
  • Make any surface antithrombotic
  • Qvanteq is using MedtechVault
  • In-vitro thrombogenicity screening capacity

Qvanteq AG

Technoparkstr. 1, 8005 Zürich, Switzerland
+41 44 500 98 90
info@qvanteq.com

More

  • Meet us
  • Subscribe
  • Contact
  • Disclaimer
Copyright Qvanteq AG